{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360869855573658880.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1016/j.msard.2024.106176"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S2211034824007521?httpAccept=text/xml"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S2211034824007521?httpAccept=text/plain"}}],"resourceType":"学術雑誌論文(journal article)","dc:title":[{"@value":"The real-world impact of biologics for NMOSD: A retrospective single-center study compared with natural course and conventional treatments in Japanese"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380869855573658895","@type":"Researcher","foaf:name":[{"@value":"Naoya Yamazaki"}]},{"@id":"https://cir.nii.ac.jp/crid/1380869855573658910","@type":"Researcher","foaf:name":[{"@value":"Tatsuro Misu"}]},{"@id":"https://cir.nii.ac.jp/crid/1380869855573658892","@type":"Researcher","foaf:name":[{"@value":"Yuki Matsumoto"}]},{"@id":"https://cir.nii.ac.jp/crid/1380869855573658753","@type":"Researcher","foaf:name":[{"@value":"Yoshiki Takai"}]},{"@id":"https://cir.nii.ac.jp/crid/1380869855573658754","@type":"Researcher","foaf:name":[{"@value":"Chihiro Namatame"}]},{"@id":"https://cir.nii.ac.jp/crid/1380869855573658906","@type":"Researcher","foaf:name":[{"@value":"Hirohiko Ono"}]},{"@id":"https://cir.nii.ac.jp/crid/1380869855573658900","@type":"Researcher","foaf:name":[{"@value":"Kimihiko Kaneko"}]},{"@id":"https://cir.nii.ac.jp/crid/1380869855573658893","@type":"Researcher","foaf:name":[{"@value":"Shuhei Nishiyama"}]},{"@id":"https://cir.nii.ac.jp/crid/1380869855573658756","@type":"Researcher","foaf:name":[{"@value":"Hiroshi Kuroda"}]},{"@id":"https://cir.nii.ac.jp/crid/1380869855573658918","@type":"Researcher","foaf:name":[{"@value":"Toshiyuki Takahashi"}]},{"@id":"https://cir.nii.ac.jp/crid/1380869855573658912","@type":"Researcher","foaf:name":[{"@value":"Ichiro Nakashima"}]},{"@id":"https://cir.nii.ac.jp/crid/1380869855573658923","@type":"Researcher","foaf:name":[{"@value":"Kazuo Fujihara"}]},{"@id":"https://cir.nii.ac.jp/crid/1380869855573658916","@type":"Researcher","foaf:name":[{"@value":"Masashi Aoki"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"22110348"}],"prism:publicationName":[{"@value":"Multiple Sclerosis and Related Disorders"}],"dc:publisher":[{"@value":"Elsevier BV"}],"prism:publicationDate":"2024-12","prism:volume":"92","prism:startingPage":"106176"},"reviewed":"false","dc:rights":["https://www.elsevier.com/tdm/userlicense/1.0/","https://www.elsevier.com/legal/tdmrep-license","http://www.elsevier.com/open-access/userlicense/1.0/","https://doi.org/10.15223/policy-017","https://doi.org/10.15223/policy-037","https://doi.org/10.15223/policy-012","https://doi.org/10.15223/policy-029","https://doi.org/10.15223/policy-004"],"url":[{"@id":"https://api.elsevier.com/content/article/PII:S2211034824007521?httpAccept=text/xml"},{"@id":"https://api.elsevier.com/content/article/PII:S2211034824007521?httpAccept=text/plain"}],"createdAt":"2024-11-16","modifiedAt":"2025-09-08","project":[{"@id":"https://cir.nii.ac.jp/crid/1040858752026756608","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"23K06959"},{"@type":"JGN","@value":"JP23K06959"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23K06959/"}],"notation":[{"@language":"ja","@value":"脱髄性疾患MOG抗体関連疾患の中枢神経内免疫病態の解明"},{"@language":"en","@value":"Research on the pathomechanism of neuroinflammation and demyelination in MOG antibody associated disorders"}]}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050018904748235520","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Efficacy and safety of mycophenolate mofetil for steroid reduction in neuromyelitis optica spectrum disorder: a prospective cohort study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360009142459832320","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011145153165056","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica"}]},{"@id":"https://cir.nii.ac.jp/crid/1360020700265730048","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Ravulizumab in Aquaporin‐4–Positive Neuromyelitis Optica Spectrum Disorder"}]},{"@id":"https://cir.nii.ac.jp/crid/1360020700266363136","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Exploring steroid tapering in patients with neuromyelitis optica spectrum disorder treated with satralizumab in SAkuraSky: A case series"}]},{"@id":"https://cir.nii.ac.jp/crid/1360025434014012416","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Long-term safety and effectiveness of eculizumab in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a 2-year interim analysis of post-marketing surveillance in Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1360286993686614656","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder"}]},{"@id":"https://cir.nii.ac.jp/crid/1360298345518616960","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar"}]},{"@id":"https://cir.nii.ac.jp/crid/1360305194099671552","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"International Delphi Consensus on the Management of AQP4-IgG+ NMOSD"}]},{"@id":"https://cir.nii.ac.jp/crid/1360306905166992896","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Clinical practice guidelines for multiple sclerosis, neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody-associated disease 2023 in Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1360306914269093632","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Asian and African/Caribbean AQP4-NMOSD patient outcomes according to self-identified race and place of residence"}]},{"@id":"https://cir.nii.ac.jp/crid/1360306914346379776","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Efficacy and safety of inebilizumab in Asian participants with neuromyelitis optica spectrum disorder: Subgroup analyses of the N-MOmentum study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565169025925888","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders"}]},{"@id":"https://cir.nii.ac.jp/crid/1360568468663323136","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder"}]},{"@id":"https://cir.nii.ac.jp/crid/1360572092858758784","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574094763614976","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574095793813376","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Azathioprine"}]},{"@id":"https://cir.nii.ac.jp/crid/1360583650977844864","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Long-term Efficacy of Satralizumab in AQP4-IgG–Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar"}]},{"@id":"https://cir.nii.ac.jp/crid/1360588389225783552","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Adverse Events in NMOSD Therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848659480154496","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders"}]},{"@id":"https://cir.nii.ac.jp/crid/1360861710914617984","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4–immunoglobulin G–seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1360865123388097536","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature."}]},{"@id":"https://cir.nii.ac.jp/crid/1360869859059832576","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Tacrolimus is effective for neuromyelitis optica spectrum disorders with or without anti-AQP4 antibody"}]},{"@id":"https://cir.nii.ac.jp/crid/1360869859944370304","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension"}]},{"@id":"https://cir.nii.ac.jp/crid/1360869864293393152","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137043439761664","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis optica"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137045920278656","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Corticosteroid and tacrolimus treatment in neuromyelitis optica related disorders"}]},{"@id":"https://cir.nii.ac.jp/crid/1361412892426168192","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418519708060928","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS)"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699993531100032","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Modelling recurrent events: a tutorial for analysis in epidemiology"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981468729909376","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Neuromyelitis optica spectrum disorders with unevenly clustered attack occurrence"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388844094817152","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670319972142208","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233268629286144","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233269600617856","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response"}]},{"@id":"https://cir.nii.ac.jp/crid/1370869855573658887","@type":"Product","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management"}]},{"@id":"https://cir.nii.ac.jp/crid/1370869855573658893","@type":"Product","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"AQP4-IgG autoimmunity in Japan and Germany: Differences in clinical profiles and prognosis in seropositive neuromyelitis optica spectrum disorders"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679216071424","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Establishment of a New Sensitive Assay for Anti-Human Aquaporin-4 Antibody in Neuromyelitis Optica"}]},{"@id":"https://cir.nii.ac.jp/crid/1390870297797552128","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Progress in the Treatment of Neuromyelitis Optica Spectrum Disorder: From Pathogenic Insights to Biologics"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1016/j.msard.2024.106176"},{"@type":"KAKEN","@value":"PRODUCT-25722547"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.6772-25_references_DOI_KWAc9l2piPHo6rAGwJILqYN0wq8"}]}